Results 111 to 120 of about 492,703 (122)

Simple Spectrophotometric Method for Estimation of Raltegravir Potassium in Bulk and Pharmaceutical Formulations

, 2013
Girija Balasaheb Bhavar, Sanjay S. Pekamwar, Kiran Balasaheb Aher, Sanjay R. Chaudhari   +3 more
openalex  

Some of the next articles are maybe not open access.

Related searches:

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study

Lancet Infectious Diseases, The, 2012
Bonaventura Clotet, Nicolas A Margot
exaly  

Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection

Journal of Acquired Immune Deficiency Syndromes (1999), 2007
Michael D Miller
exaly  

Short‐Course Raltegravir Intensification Does Not Reduce Persistent Low‐Level Viremia in Patients with HIV‐1 Suppression during Receipt of Combination Antiretroviral Therapy

Clinical Infectious Diseases, 2010
Stephen J Gange
exaly  

Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro

Antimicrobial Agents and Chemotherapy, 2008
Luba Tchertanov, Jean-François Mouscadet   +1 more
exaly  

Reverse Phase - High Performance Liquid Chromatography and Ultra Violet Spectrophotometric Method for The Estimation of Raltegravir Potassium in Bulk and in Tablet Dosage form

, 2011
T. Sudha, T. Raghupathi
openalex  

Long‐Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment‐Experienced Patients with Drug‐Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials

Clinical Infectious Diseases, 2010
Joseph J Eron, Jose M Gatell, Mauro Schechter   +2 more
exaly  

Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

New England Journal of Medicine, 2008
Mauro Schechter, Mona R Loutfy, Jeffrey L Lennox   +2 more
exaly  

Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients

Journal of Acquired Immune Deficiency Syndromes (1999), 2013
Jeffrey L Lennox
exaly  

Adverse events of raltegravir and dolutegravir

Aids, 2017
Hansjakob Furrer, Huldrych F Gunthard
exaly